ClinicalTrials.gg

Program

andamertinib

Also written as “PLB1004”, “PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy” and “RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Furthest: phase 3, since Jan 31, 202410 company-led studies, 9 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Avistone Biotechnology87 open or runningphase 3since Jan 31, 2024Apr 13, 2022Nov 2026phase 2 · NCT07336732
Avistone Pharmaceutical(Ningbo)11 open or runningphase 2since Jun 24, 2025Jun 24, 2025Mar 8, 2028phase 2 · NCT07063329
Beijing Pearl Biotechnology Limited Liability11 open or runningphase 2since Nov 4, 2025Nov 4, 2025Dec 2029phase 2 · NCT07285148

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 13, 2022First study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Avistone BiotechnologyAvistone Biotechnology · NCT05347628 · 91 enrolled · China
  2. Aug 18, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06015503 · 139 enrolled · China
  3. Sep 6, 2023Phase 1 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06046495 · 81 planned · United States
  4. Jan 31, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06281964 · 327 planned · China
  5. Mar 21, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06343064 · 156 planned · China
  6. Aug 25, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06574347 · 120 planned · China
  7. Apr 25, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06970782 · 278 planned
  8. Jun 24, 2025Avistone Pharmaceutical(Ningbo)'s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Avistone Pharmaceutical(Ningbo)Avistone Pharmaceutical(Ningbo) · NCT07063329 · 108 planned · China
  9. Nov 4, 2025Beijing Pearl Biotechnology Limited Liability's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Beijing Pearl Biotechnology Limited LiabilityBeijing Pearl Biotechnology Limited Liability · NCT07285148 · 253 planned · United States
  10. Dec 18, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT07336732 · 40 planned · China

Ahead

  1. Nov 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT07336732
  2. Dec 31, 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06343064
  3. Dec 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06970782
  4. Feb 9, 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungAvistone Biotechnology · NCT06046495

TargetBeta

EGFR →read by rule
“An orally bioavailable, mono-anilino-pyrimidine, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07336732Carcinoma, Non-Small-Cell Lung · China2RecruitingAvistone BiotechnologyNov 202640
NCT07285148Carcinoma, Non-Small-Cell Lung · United States2Not yet recruitingBeijing Pearl Biotechnology Limited LiabilityDec 2029253
NCT07063329Carcinoma, Non-Small-Cell Lung · China2RecruitingAvistone Pharmaceutical(Ningbo)Mar 8, 2028108
NCT06970782Carcinoma, Non-Small-Cell Lung3Not yet recruitingAvistone BiotechnologyDec 31, 2027278
NCT06574347Carcinoma, Non-Small-Cell Lung · China2RecruitingAvistone BiotechnologyOct 31, 2026120
NCT06343064Carcinoma, Non-Small-Cell Lung · China2RecruitingAvistone BiotechnologyDec 31, 2026156
NCT06281964Carcinoma, Non-Small-Cell Lung · China3By invitationAvistone BiotechnologyJun 30, 2028327
NCT06046495Carcinoma, Non-Small-Cell Lung · United States1RecruitingAvistone BiotechnologyFeb 9, 202881
NCT06015503Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingAvistone BiotechnologyMar 6, 2025139
NCT05347628Carcinoma, Non-Small-Cell Lung · China1UNKNOWNAvistone BiotechnologyApr 4, 202391

How it is read

Names in the registry

  • “PLB1004”, 8 entries
  • “PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy”, 2 entries
  • “RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy”, 2 entries
  • “ANS014004 + PLB1004”, 1 entry

Codes read as this program: PLB1004.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.